CD40 activation of BCP-ALL cells generates IL-10-producing, IL-12-defective APCs that induce allogeneic T-cell anergy.
暂无分享,去创建一个
P. Allavena | A. Biondi | M. Bonamino | M. Vulcano | G. D'Amico | E. Biagi | C. Bugarin | G. Bianchi | V. Marin | G. Pirovano
[1] M. Brown,et al. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. , 2006, Blood.
[2] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[3] D. Neuberg,et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Kastelein,et al. Novel IL-12 family members shed light on the orchestration of Th1 responses , 2003, Trends in Immunology.
[5] G. Trinchieri,et al. Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.
[6] M. Roncarolo,et al. The Role of IL-10 and TGF-β in the Differentiation and Effector Function of T Regulatory Cells , 2002, International Archives of Allergy and Immunology.
[7] R. Stripecke,et al. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods , 2002, Leukemia.
[8] M. Introna,et al. CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-γ production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia , 2002, Leukemia.
[9] M. Brenner,et al. Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. , 2002, Blood.
[10] R. Rabin,et al. Human B Cells Become Highly Responsive to Macrophage-Inflammatory Protein-3α/CC Chemokine Ligand-20 After Cellular Activation Without Changes in CCR6 Expression or Ligand Binding , 2002, The Journal of Immunology.
[11] F. Sinigaglia,et al. Modulation of chemokine receptor expression and chemotactic responsiveness during differentiation of human naive T cells into Th1 or Th2 cells , 2002, European journal of immunology.
[12] F. Sallusto,et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22 , 2002, European journal of immunology.
[13] H. Hamada,et al. CD40 Ligand Promotes Priming of Fully Potent Antitumor CD4+ T Cells in Draining Lymph Nodes in the Presence of Apoptotic Tumor Cells , 2001, The Journal of Immunology.
[14] D. Campana,et al. Childhood acute lymphoblastic leukaemia--current status and future perspectives. , 2001, The Lancet. Oncology.
[15] A. Iellem,et al. Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.
[16] M. Roncarolo,et al. Type 1 T regulatory cells , 2001, Immunological reviews.
[17] C. Rooney,et al. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy. , 2001, Experimental hematology.
[18] S. Sallan,et al. Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. , 2001, Blood.
[19] P. Allavena,et al. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses. , 2001, The Journal of clinical investigation.
[20] R. Hurwitz,et al. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. , 2001, Human gene therapy.
[21] P. Allavena,et al. Dendritic cells as a major source of macrophage‐derived chemokine/CCL22 in vitro and in vivo , 2001, European journal of immunology.
[22] M. Urashima,et al. CD40 Ligand Immunotherapy in Cancer: An Efficient Approach , 2001, Leukemia & lymphoma.
[23] J Wagner,et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.
[24] P. Allavena,et al. Uncoupling of inflammatory chemokine receptors by IL-10: generation of functional decoys , 2000, Nature Immunology.
[25] S. H. van der Burg,et al. Strategies for immunotherapy of cancer. , 2000, Advances in immunology.
[26] S. Sallan,et al. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. , 1999, Blood.
[27] D. Olive,et al. What is the real role of CD40 in cancer immunotherapy? , 1999, Immunology today.
[28] E. Wolf,et al. CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs , 1999, Cell.
[29] G Bellone,et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. , 1999, The American journal of pathology.
[30] J. Gribben,et al. Human Non-Germinal Center B Cell Interleukin (IL)-12 Production Is Primarily Regulated by T Cell Signals CD40 Ligand, Interferon γ, and IL-10: Role of B Cells in the Maintenance of T Cell Responses , 1999, The Journal of experimental medicine.
[31] C. Mackay,et al. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. , 1998, Immunology today.
[32] R Bonecchi,et al. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. , 1998, Journal of immunology.
[33] F. Lemonnier,et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. , 1998, The Journal of clinical investigation.
[34] P. Allavena,et al. Adhesion, transendothelial migration, and reverse transmigration of in vitro cultured dendritic cells. , 1998, Blood.
[35] J. Cyster,et al. Epstein-Barr Virus–induced Molecule 1 Ligand Chemokine Is Expressed by Dendritic Cells in Lymphoid Tissues and Strongly Attracts Naive T Cells and Activated B Cells , 1998, The Journal of experimental medicine.
[36] T. Kipps,et al. Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.
[37] J. Cyster,et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[38] P. Allavena,et al. Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.
[39] P. Allavena,et al. IL‐10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages , 1998, European journal of immunology.
[40] J. Gribben,et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. , 1997, The Journal of clinical investigation.
[41] H. Gadner,et al. The Present Role of Bone Marrow and Stem Cell Transplantation in the Therapy of Children with Acute Leukemia , 1997, Annals of the New York Academy of Sciences.
[42] J. Gribben,et al. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. , 1997, Blood.
[43] J. Ceuppens,et al. CD40 triggering of chronic lymphocytic leukemia B cells results in efficient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules , 1997, Leukemia.
[44] A. Lanzavecchia,et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation , 1996, The Journal of experimental medicine.
[45] J. Louis,et al. Genetically resistant mice lacking interleukin‐12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response , 1996, European journal of immunology.
[46] D. Carvajal,et al. IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine Responses , 1996 .
[47] D. Carvajal,et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. , 1996, Immunity.
[48] D. Carvajal,et al. Mouse interleukin‐12 (IL‐12) p40 homodimer: a potent IL‐12 antagonist , 1995, European journal of immunology.
[49] J. Banchereau,et al. The CD40 antigen and its ligand. , 1994, Annual review of immunology.
[50] T. Kipps,et al. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal , 1993, The Journal of experimental medicine.
[51] Giorgio,et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells , 1992, The Journal of experimental medicine.
[52] F. Behm,et al. Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia. , 1992, Blood.
[53] F. Colotta,et al. Arachidonic acid and leukotriene B4 induce aggregation of human peripheral blood mononuclear leucocytes in vitro , 1984, British journal of haematology.
[54] D. H. Mellor,et al. Real time , 1981 .